SMITH & NEPHEW ANNUAL REPORT 2016 169 GROUP INFORMATION BUSINESS OVERVIEW AND GROUP HISTORY Smith & Nephews operations are organised into geographical selling regions and product franchises within the medical technology industry.
The Group has a history dating back 160 years to the family enterprise of Thomas James Smith who opened a small pharmacy in Hull, UK in 1856.
Following his death in 1896, his nephew Horatio Nelson Smith took over the management of the business.
By the late 1990s, Smith & Nephew had expanded into being a diverse healthcare conglomerate with operations across the globe, producing YDULRXVPHGLFDO GHYLFHV SHUVRQDO FDUH SURGXFWV DQG WUDGLWLRQDO DQG DGYDQFHG ZRXQG FDUH WUHDWPHQWV, Q 6PLWK 1HSKHZ DQQRXQFHG D major restructuring to focus management attention and investment on three global business units Advanced Wound Management, Endoscopy and Orthopaedics which offered high growth and margin opportunities.
In 2011, the Endoscopy and Orthopaedics businesses were brought together to create an Advanced Surgical Devices division.
In 2015, the Advanced Wound Management and Advanced Surgical Devices divisions were brought together to form a global business across nine product franchises, managed as three geographical selling regions with global functions for operations, R&D and corporate support functions.
Smith & Nephew was incorporated and listed on the London Stock Exchange in 1937 and in 1999 the Group was also listed on the New York Stock Exchange.
In 2001, Smith & Nephew became a constituent member of the FTSE 100 index in the UK.
This means that Smith & Nephew is included LQWKHWRS FRPSDQLHV WUDGHG RQ WKH RQGRQ 6WRFN [FKDQJH PHDVXUHG LQ WHUPV RI PDUNHW FDSLWDOLVDWLRQ Today, Smith & Nephew is a public limited company incorporated and headquartered in the UK and carries out business around the world.
PROPERTY, PLANT AND EQUIPMENT The table below summarises the main properties which the Group uses and their approximate areas.
Approximate area square feet 000s URXS KHDG RIFH LQ RQGRQ 8.
22 2IFH DQG VXUJLFDO WUDLQLQJ IDFLOLW LQ &UR[OH 3DUN :DWIRUG 8.
60 Regional headquarters in Andover, Massachusetts, US 144 0DQXIDFWXULQJ UHVHDUFK DQG RIFH IDFLOLW LQ XOO 8.
473 0DQXIDFWXULQJ DQG RIFH IDFLOLWLHV LQ 0HPSKLV 7HQQHVVHH 86 968 Distribution facility in Memphis, Tennessee, US 248 Manufacturing facility in Aarau, Switzerland 121 Manufacturing facility in Beijing, China 192 Manufacturing facility in Tuttlingen, Germany 50 Distribution facility and regional headquarters in Baar, Switzerland 71 0DQXIDFWXULQJ IDFLOLW LQ 0DQVHOG 0DVVDFKXVHWWV 86 98 Manufacturing facility in Oklahoma City, Oklahoma, US 155 0DQXIDFWXULQJ UHVHDUFK DQG RIFH IDFLOLW LQ $XVWLQ 7H[DV 86 157 Manufacturing facilities in La Aurora and Alajuela, Costa Rica 292 Research facility in Irvine, California, US 23 Manufacturing facility in Devrukh, India 74 Manufacturing facility in Suzhou, China 288 Bioactives headquarters and laboratory space in Fort Worth, Texas, US 165 Manufacturing facility in Curaao, Dutch Caribbean 16 The Group Global Operations strategy includes ongoing assessment of the optimal facility footprint.
The Advanced Surgical Devices manufacturing facilities in Memphis, Tennessee are largely freehold, a portion of Tuttlingen and the Advanced Wound Management facilities in Hull are freehold while other principal locations are leasehold.
The Group has freehold and leasehold interests in real estate in other countries throughout the world, but no other LV LQGLYLGXDOO VLJQLFDQW WR WKH URXS :KHUH UHTXLUHG WKH DSSURSULDWH JRYHUQPHQWDO DXWKRULWLHV KDYH DSSURYHG WKH IDFLOLWLHV OFF-BALANCE SHEET ARRANGEMENTS 0DQDJHPHQW EHOLHYHV WKDW WKH URXS GRHV QRW KDYH DQ RII EDODQFH VKHHW DUUDQJHPHQWV DV GHQHG E WKH 6 & LQ LWHP RI RUP WKDW KDYH RU DUH UHDVRQDEO OLNHO WR KDYH D FXUUHQW RU IXWXUH HIIHFW RQ WKH URXSV QDQFLDO FRQGLWLRQ FKDQJHV LQ QDQFLDO FRQGLWLRQ UHYHQXHV RU H[SHQVHV UHVXOWV RIRSHUDWLRQV OLTXLGLW FDSLWDO H[SHQGLWXUHV RU FDSLWDO UHVRXUFHV WKDW LV PDWHULDO WR LQYHVWRUV RELATED PARTY TRANSACTIONS Except for transactions with associates see Note 23.2 of Notes to the Group accounts, no other related party had material transactions or loans with 6PLWK 1HSKHZ RYHU WKH ODVW WKUHH QDQFLDO HDUV RISK FACTORS There are known and unknown risks and uncertainties relating to Smith & Nephews business.
The factors listed on pages 170 to 172 could cause WKH URXSV EXVLQHVV QDQFLDO SRVLWLRQ DQG UHVXOWV RI RSHUDWLRQV WR GLIIHU PDWHULDOO DQG DGYHUVHO IURP H[SHFWHG DQG KLVWRULFDO OHYHOV, Q DGGLWLRQ RWKHU IDFWRUV QRW OLVWHG KHUH WKDW 6PLWK 1HSKHZ FDQQRW SUHVHQWO LGHQWLI RU GRHV QRW EHOLHYH WR EH HTXDOO VLJQLFDQW FRXOG DOVR PDWHULDOO DGYHUVHO DIIHFW 6PLWK 1HSKHZV EXVLQHVV QDQFLDO SRVLWLRQ RU UHVXOWV RI RSHUDWLRQV SMITH & NEPHEW ANNUAL REPORT 2016 170 GROUP INFORMATION Highly competitive markets Dependence on government and other funding The Group competes across a diverse range of geographic and product In most markets throughout the world, expenditure on medical devices is markets.
Each market in which the Group operates contains a number of ultimately controlled to a large extent by governments.
Funds may be made different competitors, including specialised and international corporations.
available or withdrawn from healthcare budgets depending on government 6LJQLFDQW SURGXFW LQQRYDWLRQV WHFKQLFDO DGYDQFHV RU WKH LQWHQVLFDWLRQ policy.
The Group is therefore largely dependent on future governments of price competition by competitors could adversely affect the Groups providing increased funds commensurate with the increased demand operating results.
6RPH RI WKHVH FRPSHWLWRUV PD KDYH JUHDWHU QDQFLDO PDUNHWLQJ DQG Pricing of the Groups products is largely governed in most markets other resources than Smith & Nephew.
These competitors may be by governmental reimbursement authorities.
Initiatives sponsored by DEOH WR LQLWLDWH WHFKQRORJLFDO DGYDQFHV LQ WKH HOG GHOLYHU SURGXFWV RQ government agencies, legislative bodies and the private sector to limit more attractive terms, more aggressively market their products or invest the growth of healthcare costs, including price regulation, excise taxes larger amounts of capital and research and development R&D into and competitive pricing, are ongoing in markets where the Group has their businesses.
This control may be exercised by determining prices for an individual product or for an entire procedure.
The Group is exposed to There is a possibility of further consolidation of competitors, which could government policies favouring locally sourced products.
The Group is also adversely affect the Groups ability to compete with larger companies due exposed to changes in reimbursement policy, tax policy and pricing which WR LQVXIFLHQW QDQFLDO UHVRXUFHV, I DQ RI WKH URXSV EXVLQHVVHV ZHUH PD KDYH DQ DGYHUVH LPSDFW RQ UHYHQXH DQG RSHUDWLQJ SURW 3URYLVLRQV to lose market share or achieve lower than expected revenue growth, LQ 86 KHDOWKFDUH OHJLVODWLRQ ZKLFK SUHYLRXVO LPSRVHG VLJQLFDQW WD[HV RQ WKHUHFRXOG EH D GLVSURSRUWLRQDWH DGYHUVH LPSDFW RQ WKH URXSV VKDUH medical device manufacturers have been suspended for two years but price and its strategic options.
There may be an increased risk of adverse changes to Competition exists among healthcare providers to gain patients on the government funding policies arising from deterioration in macro-economic basis of quality, service and price.
There has been some consolidation in conditions from time to time in the Groups markets.
the Groups customer base and this trend is expected to continue.
Some The Group must adhere to the rules laid down by government agencies customers have joined group purchasing organisations or introduced that fund or regulate healthcare, including extensive and complex rules in other cost containment measures that could lead to downward pressure WKH 86 DLOXUH WR GR VR FRXOG UHVXOW LQ QHV RU ORVV RI IXWXUH IXQGLQJ on prices or limit the number of suppliers in certain business areas, ZKLFKFRXOG DGYHUVHO DIIHFW 6PLWK 1HSKHZV UHVXOWV RI RSHUDWLRQV DQG World economic conditions hinder its growth potential.
Demand for the Groups products is driven by demographic trends, including the ageing population and the incidence of osteoporosis and Continual development and introduction of new products obesity.
Supply of, use of and payment for the Groups products are also The medical devices industry has a rapid rate of new product introduction.
LQXHQFHG E ZRUOG HFRQRPLF FRQGLWLRQV ZKLFK FRXOG SODFH LQFUHDVHG In order to remain competitive, the Group must continue to develop pressure on demand and pricing, adversely impacting the Groups ability innovative products that satisfy customer needs and preferences or to deliver revenue and margin growth.
The conditions could favour larger, provide cost or other advantages.
Developing new products is a costly, better capitalised groups, with higher market shares and margins.
As lengthy and uncertain process.
The Group may fail to innovate due to low a consequence, the Groups prosperity is linked to general economic R&D investment, a R&D skills gap or poor product development.
A potential conditions and there is a risk of deterioration of the Groups performance product may not be brought to market or not succeed in the market for any DQG QDQFHV GXULQJ DGYHUVH PDFUR HFRQRPLF FRQGLWLRQV number of reasons, including failure to work optimally, failure to receive regulatory approval, failure to be cost-competitive, infringement of patents During 2016, economic conditions worldwide continued to create or other intellectual property rights and changes in consumer demand.
The several challenges for the Group, including deferrals of joint replacement Groups products and technologies are also subject to marketing attack by SURFHGXUHV KHLJKWHQHG SULFLQJ SUHVVXUH VLJQLFDQW GHFOLQHV LQ FDSLWDO competitors.
Furthermore, new products that are developed and marketed equipment expenditures at hospitals notably in China and increased by the Groups competitors may affect price levels in the various markets uncertainty over the collectability of government debt, particularly those in in which the Group operates.
If the Groups new products do not remain the Emerging Markets and the oil-dependent Gulf States.
These factors competitive with those of competitors, the Groups revenue could decline.
tempered the overall growth of the Groups global markets and could have an increased impact on growth in the future.
The Group maintains reserves for excess and obsolete inventory resulting from the potential inability to sell its products at prices in excess of current Political uncertainties carrying costs.
Marketplace changes resulting from the introduction of new The Group operates on a worldwide basis and has distribution channels, products or surgical procedures may cause some of the Groups products purchasing agents and buying entities in over 100 countries.
The Group makes estimates regarding the future upheaval in some of those countries or in surrounding regions may recoverability of the costs of these products and records a provision for impact the Groups results of operations.
Political changes in a country excess and obsolete inventories based on historical experience, expiration FRXOG SUHYHQW WKH URXS IURP UHFHLYLQJ UHPLWWDQFHV RI SURW IURP D of sterilisation dates and expected future trends.
If actual product life member of the Group located in that country or from selling its products cycles, product demand or acceptance of new product introductions are or investments in that country.
Furthermore, changes in government policy less favourable than projected by management, additional inventory writeregarding preference for local suppliers, import quotas, taxation or other downs may be required.
PDWWHUV FRXOG DGYHUVHO DIIHFW WKH URXSV UHYHQXH DQG RSHUDWLQJ SURW :DU HFRQRPLF VDQFWLRQV WHUURULVW DFWLYLWLHV RU RWKHU FRQLFW FRXOG DOVR adversely impact the Group.
These risks may be greater in Emerging 0DUNHWV ZKLFK DFFRXQW IRU DQLQFUHDVLQJ SRUWLRQ RI WKH URXSV EXVLQHVV During 2016, the outcome of the UK referendum regarding the EU and the pending change in administration in the United States have added to political uncertainty.
SMITH & NEPHEW ANNUAL REPORT 2016 171 GROUP INFORMATION &XUUHQF XFWXDWLRQV product development or if its largest sales forces suffer disruption or XSKHDYDO LWV UHYHQXH DQG RSHUDWLQJ SURW ZRXOG EH DGYHUVHO DIIHFWHG Smith & Nephews results of operations are affected by transactional Additionally, if the Group is unable to recruit, hire, develop and retain a exchange rate movements in that they are subject to exposures arising talented, competitive workforce, it may not be able to meet its strategic from revenue in a currency different from the related costs and expenses.
The Groups manufacturing cost base is situated principally in the US, the 8.
&KLQD DQG 6ZLW]HUODQG IURP ZKLFK QLVKHG SURGXFWV DUH H[SRUWHG WR Proprietary rights and patents the Groups selling operations worldwide.
Thus, the Group is exposed to Due to the technological nature of medical devices and the Groups XFWXDWLRQV LQ H[FKDQJH UDWHV EHWZHHQ WKH 86 'ROODU 6WHUOLQJ DQG 6ZLVV emphasis on serving its customers with innovative products, the Group Franc and the currency of the Groups selling operations, particularly the has been subject to patent infringement claims and is subject to the XUR $XVWUDOLDQ 'ROODU DQGDSDQHVH HQ, IWKH 86 'ROODU 6WHUOLQJ RU potential for additional claims.
Swiss Franc should strengthen against the Euro, Australian Dollar and the Japanese Yen, the Groups trading margin could be adversely affected.
Claims asserted by third parties regarding infringement of their intellectual property rights, if successful, could require the Group to expend time and The Group manages the impact of exchange rate movements on revenue VLJQLFDQW UHVRXUFHV WR SD GDPDJHV GHYHORS QRQ LQIULQJLQJ SURGXFWV and cost of goods sold by a policy of transacting forward foreign currency or obtain licences to the products which are the subject of such litigation, FRPPLWPHQWV ZKHQ UP SXUFKDVH RUGHUV DUH SODFHG, Q DGGLWLRQ WKH WKHUHE DIIHFWLQJ WKH URXSV JURZWK DQG SURWDELOLW 6PLWK 1HSKHZ Groups policy is for forecast transactions to be covered between 50% attempts to protect its intellectual property and regularly opposes third and 90% for up to one year.
However, the Group is exposed to medium party patents and trademarks where appropriate in those areas that WRORQJ WHUP DGYHUVH PRYHPHQWV LQ WKH VWUHQJWK RI FXUUHQFLHV FRPSDUHG PLJKW FRQLFW ZLWK WKH URXSV EXVLQHVV LQWHUHVWV, I 6PLWK 1HSKHZ WRWKH 86 'ROODU fails to protect and enforce its intellectual property rights successfully, The Group uses the US Dollar as its reporting currency and the US Dollar its competitive position could suffer, which could harm its results is the functional currency of Smith & Nephew plc.
The Groups revenues, of operations.
SURWV DQG HDUQLQJV DUH DOVR DIIHFWHG E H[FKDQJH UDWH PRYHPHQWV RQ Product liability claims and loss of reputation WKH WUDQVODWLRQ RI UHVXOWV RI RSHUDWLRQV LQ IRUHLJQ VXEVLGLDULHV IRU QDQFLDO reporting purposes.
See Liquidity and capital resources on page 114.
The development, manufacture and sale of medical devices entail risk of product liability claims or recalls.
Design and manufacturing defects with Manufacturing and supply respect to products sold by the Group or by companies it has acquired The Groups manufacturing production is concentrated at main facilities in could damage, or impair the repair of, body functions.
The Group may 0HPSKLV 0DQVHOG DQG 2NODKRPD &LW LQ WKH 86 XOO DQG :DUZLFN LQ WKH become subject to liability, which could be substantial, because of actual UK, Aarau in Switzerland, Tuttlingen in Germany, Devrukh in India, Suzhou or alleged defects in its products.
In addition, product defects could lead to and Beijing in China, La Aurora and Alajuela in Costa Rica, Puschino in the need to recall from the market existing products, which may be costly Russia and Curaao, in Dutch Caribbean.
If major physical disruption and harmful to the Groups reputation.
took place at any of these sites, it could adversely affect the results of There can be no assurance that customers, particularly in the US, the operations.
Physical loss and consequential loss insurance is carried to Groups largest geographical market, will not bring product liability or cover such risks but is subject to limits and deductibles and may not be related claims that would have a material adverse effect on the Groups VXIFLHQW WR FRYHU FDWDVWURSKLF ORVV 0DQDJHPHQW RI RUWKRSDHGLF LQYHQWRU QDQFLDO SRVLWLRQ RU UHVXOWV RI RSHUDWLRQV LQ WKH IXWXUH RU WKDW WKH URXS is complex, particularly forecasting and production planning.
There is a will be able to resolve such claims within insurance limits.
During 2015, risk that failures in operational execution could lead to excess inventory or developments in the Groups metal-on-metal hip implant claims led to a individual product shortages.
$203m charge being recognised relating to known and future claims.
The Group is reliant on certain key suppliers of raw materials, components, Regulatory standards and compliance in the healthcare industry QLVKHG SURGXFWV DQG SDFNDJLQJ PDWHULDOV RU LQ VRPH FDVHV RQ D VLQJOH supplier.
These suppliers must provide the materials and perform the Business practices in the healthcare industry are subject to regulation DFWLYLWLHV WRWKH URXSV VWDQGDUG RI TXDOLW UHTXLUHPHQWV and review by various government authorities.
In general, the trend in many countries in which the Group does business is towards higher A suppliers failure to meet expected quality standards could create liability expectations and increased enforcement activity by governmental for the Group and adversely affect sales of the Groups related products.
While the Group is committed to doing business with integrity The Group may be forced to pay higher prices to obtain raw materials, and welcomes the trend to higher standards in the healthcare industry, which it may not be able to pass on to its customers in the form of the Group and other companies in the industry have been subject to LQFUHDVHG SULFHV IRU LWV QLVKHG SURGXFWV, Q DGGLWLRQ VRPH RI WKH UDZ investigations and other enforcement activity that have incurred and may materials used may become unavailable, and there can be no assurance FRQWLQXH WRLQFXU VLJQLFDQW H[SHQVH 8QGHU FHUWDLQ FLUFXPVWDQFHV LI WKH that the Group will be able to obtain suitable and cost effective substitutes.
URXS ZHUH IRXQG WR KDYH YLRODWHG WKH ODZ LWVDELOLW WR VHOO LWV SURGXFWV WR Any interruption of supply caused by these or other factors could certain customers could be restricted.
QHJDWLYHO LPSDFW 6PLWK 1HSKHZV UHYHQXH DQG RSHUDWLQJ SURW International regulation The Group will, from time to time, outsource the manufacture of The Group operates across the world and is subject to extensive FRPSRQHQWV DQG QLVKHG SURGXFWV WR WKLUG SDUWLHV DQG ZLOO SHULRGLFDOO legislation, including anti-bribery and corruption and data protection, relocate the manufacture of product and or processes between existing in each country in which we operate.
Our international operations are facilities.
While these are planned activities, with these transfers there is governed in part by the UK Bribery Act and the US Foreign Corrupt DULVN RI GLVUXSWLRQ WR VXSSO Practices Act FCPA which prohibit us or our agents from making, or Attracting and retaining key personnel RIIHULQJ LPSURSHU SD PHQWV WR JRYHUQPHQW RIFLDOV DQG RWKHU SHUVRQV for the purpose of obtaining or maintaining business or product The Groups continued development depends on its ability to hire approvals.
Enforcement of such legislation has increased in recent years and retain highly-skilled personnel with particular expertise.
This is ZLWK VLJQLFDQW QHV DQG SHQDOWLHV EHLQJ LPSRVHG RQ FRPSDQLHV DQG critical, particularly in general management, research, new product individuals.
Our international operations, particularly in the Emerging development and in the sales forces.
If Smith & Nephew is unable to retain key personnel in general management, research and new SMITH & NEPHEW ANNUAL REPORT 2016 172 GROUP INFORMATION Markets, expose the Group to the risk that our employees or agents will Relationships with healthcare professionals engage in prohibited activities.
The Group seeks to maintain effective and ethical working relationships with physicians and medical personnel who assist in the research and Regulatory approval development of new products or improvements to our existing product The international medical device industry is highly regulated.
Regulatory range or in product training and medical education.
If we are unable requirements are a major factor in determining whether substances and to maintain these relationships our ability to meet the demands of our materials can be developed into marketable products and the amount of FXVWRPHUV FRXOG EH GLPLQLVKHG DQG RXU UHYHQXH DQG SURW FRXOG EH time and expense that should be allotted to such development.
National regulatory authorities administer and enforce a complex series Reliance on sophisticated information technology of laws and regulations that govern the design, development, approval, The Group uses a wide variety of information systems, programmes manufacture, labelling, marketing and sale of healthcare products.
They and technology to manage our business.
Our systems are vulnerable DOVR UHYLHZ GDWD VXSSRUWLQJ WKH VDIHW DQG HIFDF RI VXFK SURGXFWV 2I to a cyber-attack, malicious intrusion, loss of data privacy or any other particular importance is the requirement in many countries that products VLJQLFDQW GLVUXSWLRQ 2XU V VWHPV KDYH EHHQ DQG ZLOO FRQWLQXH WR EH WKH be authorised or registered prior to manufacture, marketing or sale and target of such threats.
We have systems in place to minimise the risk and that such authorisation or registration be subsequently maintained.
The disruption of these intrusions and to monitor our systems on an ongoing major regulatory agencies for Smith & Nephews products include the Food basis for current or potential threats.
There can be no assurance that and Drug Administration FDA in the US, the Medicines and Healthcare these measures will prove effective in protecting Smith & Nephew from products Regulatory Agency in the UK, the Ministry of Health, Labour future interruptions and as a result the performance of the Group could be and Welfare in Japan, the China Food and Drug Administration and the materially adversely affected.
At any time, the Group is awaiting a number of regulatory approvals which, if not received, could Other risk factors adversely affect results of operations.
Smith & Nephew is subject to a number of other risks, which are common The trend is towards more stringent regulation and higher standards of to most global medical technology groups and are reviewed as part of the technical appraisal.
Such controls have become increasingly demanding to Groups risk management process.
comply with and management believes that this trend will continue.
FACTORS AFFECTING SMITH & NEPHEWS RESULTS OF Regulatory requirements may also entail inspections for compliance with OPERATIONS appropriate standards, including those relating to Quality Management RYHUQPHQW HFRQRPLF VFDO PRQHWDU DQG SROLWLFDO SROLFLHV DUH DOO IDFWRUV Systems or Good Manufacturing Practices regulations.
All manufacturing that materially affect the Groups operation or investments of shareholders.
DQG RWKHU VLJQLFDQW IDFLOLWLHV ZLWKLQ WKH URXS DUH VXEMHFW WR UHJXODU 2WKHU IDFWRUV LQFOXGH VDOHV WUHQGV FXUUHQF XFWXDWLRQV DQG LQQRYDWLRQ internal and external audit for compliance with national and Group medical Each of these factors is discussed further in the Our Marketplace device regulation and policies.
on pages 16 to 17, Financial review on pages 39 to 41 and Taxation Payment for medical devices may be governed by reimbursement tariff information for shareholders on pages 187 to 188. agencies in a number of countries.
Reimbursement rates may be set in response to perceived economic value of the devices, based on clinical and other data relating to cost, patient outcomes and comparative effectiveness.
They may also be affected by overall government budgetary considerations.
The Group believes that its emphasis on innovative products and services should contribute to success in this environment.
Failure to comply with these regulatory requirements could have a number of adverse consequences, including withdrawal of approval to sell a SURGXFW LQ D FRXQWU WHPSRUDU FORVXUH RI D PDQXIDFWXULQJ IDFLOLW QHV and potential damage to Company reputation.
Failure to make successful acquisitions A key element of the Groups strategy for continued growth is to make acquisitions or alliances to complement its existing business.
Failure to identify appropriate acquisition targets or failure to conduct adequate due diligence or to integrate them successfully would have an adverse impact RQ WKH URXSV FRPSHWLWLYH SRVLWLRQ DQG SURWDELOLW 7KLV FRXOG UHVXOW from the diversion of management resources towards the acquisition or integration process, challenges of integrating organisations of different geographic, cultural and ethical backgrounds, as well as the prospect of taking on unexpected or unknown liabilities.
In addition, the availability of JOREDO FDSLWDO PD PDNH QDQFLQJ OHVV DWWDLQDEOH RU PRUH H[SHQVLYH DQG could result in the Group failing in its strategic aim of growth by acquisition or alliance.
